Details of the Drug

General Information of Drug (ID: DMCT31R)

Drug Name

Carbinoxamine

Synonyms

Allergefon; Carbinoxamina; Carbinoxaminum; Clistin; Clistine; Paracarbinoxamine; Paracarinoxamine; Rotoxamine; Carbinoxamine base; Carbinoxamina [INN-Spanish]; Carbinoxamine (INN); Carbinoxamine [INN:BAN]; Carbinoxaminum [INN-Latin]; Clistin (TN); McN-R 73Z; Palgic (TN); {2-[(4-Chlorophenyl)-2-pyridylmethoxy]ethyl}dimethylamine; N,N-Dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine; Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-(9CI); (+-)-Carbinoxamine; 2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine; 2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine; 2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine

Indication

Disease Entry	ICD 11	Status	REF
Vasomotor/allergic rhinitis	CA08	Approved	[1]

Therapeutic Class

Antihistamines

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

290.79

Topological Polar Surface Area (xlogp)

2.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 - 20 hours [3]

Chemical Identifiers

Formula: C16H19ClN2O
IUPAC Name: 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
Canonical SMILES: CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
InChI: InChI=1S/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3
InChIKey: OJFSXZCBGQGRNV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2564
ChEBI ID: CHEBI:3398
CAS Number: 486-16-8
DrugBank ID: DB00748
TTD ID: D00FGV

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[4]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Vasomotor/allergic rhinitis

ICD Disease Classification

CA08

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Carbinoxamine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Methdilazine	DMAUHQX	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[14]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[13]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[13]
-----------

Coadministration of a Drug Treating the Disease Different from Carbinoxamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[14]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[13]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Memantine.	Alzheimer disease [8A20]	[13]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Carbinoxamine when combined with Rivastigmine.	Alzheimer disease [8A20]	[15]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Carbinoxamine when combined with Donepezil.	Alzheimer disease [8A20]	[15]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[13]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Cariprazine.	Bipolar disorder [6A60]	[13]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Carbinoxamine and Loperamide.	Bowel habit change [ME05]	[16]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Carbinoxamine when combined with Acetylcholine.	Cataract [9B10]	[17]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[18]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[18]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[18]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Olopatadine.	Conjunctiva disorder [9A60]	[19]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Ethanol.	Cystitis [GC00]	[19]
Cyclobenzaprine	DM1YBRM	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[13]
Isocarboxazid	DMAF1NB	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Isocarboxazid.	Depression [6A70-6A7Z]	[20]
Tranylcypromine	DMGB5RE	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Tranylcypromine.	Depression [6A70-6A7Z]	[20]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and OPC-34712.	Depression [6A70-6A7Z]	[13]
Phenelzine	DMHIDUE	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Phenelzine.	Depression [6A70-6A7Z]	[20]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Clomipramine.	Depression [6A70-6A7Z]	[13]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Doxepin.	Depression [6A70-6A7Z]	[13]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Maprotiline.	Depression [6A70-6A7Z]	[13]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Esketamine.	Depression [6A70-6A7Z]	[21]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Mepenzolate.	Digestive system disease [DE2Z]	[13]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Oxybutynine.	Discovery agent [N.A.]	[13]
Zonisamide	DM0DTF7	Major	Additive CNS depression effects by the combination of Carbinoxamine and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[22]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[13]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Solifenacin.	Functional bladder disorder [GC50]	[13]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Tolterodine.	Functional bladder disorder [GC50]	[13]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Propantheline.	Gastric ulcer [DA60]	[13]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Carbinoxamine when combined with Pilocarpine.	Glaucoma [9C61]	[17]
Procarbazine	DMIK367	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Procarbazine.	Hodgkin lymphoma [2B30]	[20]
Potassium chloride	DMMTAJC	Major	Increased risk of GI mucosal injury/bleeding risk by the combination of Carbinoxamine and Potassium chloride.	Hypo-kalaemia [5C77]	[23]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[13]
Amantadine	DMS3YE9	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Amantadine.	Influenza [1E30-1E32]	[24]
Propiomazine	DMKY8V1	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Propiomazine.	Insomnia [7A00-7A0Z]	[13]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and ITI-007.	Insomnia [7A00-7A0Z]	[13]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Clidinium.	Irritable bowel syndrome [DD91]	[13]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Dicyclomine.	Irritable bowel syndrome [DD91]	[13]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Carbinoxamine when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[15]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[25]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Lasmiditan.	Migraine [8A80]	[26]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Flibanserin.	Mood disorder [6A60-6E23]	[27]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Thalidomide.	Multiple myeloma [2A83]	[28]
Ozanimod	DMT6AM2	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Ozanimod.	Multiple sclerosis [8A40]	[20]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Phenindamine.	Nasopharyngitis [CA00]	[13]
Dimenhydrinate	DM264B3	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Dimenhydrinate.	Nausea/vomiting [MD90]	[13]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Promethazine.	Nausea/vomiting [MD90]	[13]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Cyclizine.	Nausea/vomiting [MD90]	[13]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Carbinoxamine and Apraclonidine.	Optic nerve disorder [9C40]	[29]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Flavoxate.	Pain [MG30-MG3Z]	[13]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Biperiden.	Parkinsonism [8A00]	[13]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Orphenadrine.	Parkinsonism [8A00]	[13]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Methylscopolamine.	Peptic ulcer [DA61]	[13]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[13]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Quetiapine.	Schizophrenia [6A20]	[13]
Mesoridazine	DM2ZGAN	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Mesoridazine.	Schizophrenia [6A20]	[13]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Aripiprazole.	Schizophrenia [6A20]	[13]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Paliperidone.	Schizophrenia [6A20]	[13]
Perphenazine	DMA4MRX	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Perphenazine.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Molindone.	Schizophrenia [6A20]	[13]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Thiothixene.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Trifluoperazine.	Schizophrenia [6A20]	[13]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Carbinoxamine and Pimozide.	Schizophrenia [6A20]	[13]
-----------


⏷ Show the Full List of 67 DDI Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4.
5	Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
6	Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
7	Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
8	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
9	Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
10	Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
11	Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
12	Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
13	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
14	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
15	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
16	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
17	Multum Information Services, Inc. Expert Review Panel.
18	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
19	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
20	Canadian Pharmacists Association.
21	Cerner Multum, Inc. "Australian Product Information.".
22	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
23	Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
24	Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
25	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
26	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
27	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
28	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
29	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.